HCM
SCLN

Highbridge Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Highbridge Capital Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-23,221
Closed -$228K – 1983
2015
Q2 		$228K Buy
+23,221
New +$212K ﹤0.01% 1240

Other funds holding SCLN

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return

Highbridge Capital Management's SCLN Position: Q3 2015 in Review

Highbridge Capital Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2015, closing a stake of 23,221 shares — an estimated $228K sold.

Highbridge Capital Management first reported a position in SCLN in Q2 2015 and held it in 1 quarter. The position peaked at $228K in Q2 2015. 134 funds tracked by Wall St. Rank hold SCLN as of Q3 2015.

  • Highbridge Capital Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
  • Highbridge Capital Management sold 23,221 Sciclone Pharmaceuticals Inc shares in Q3 2015, an estimated $228K.
  • Highbridge Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q2 2015 and held it in 1 quarter.
  • Highbridge Capital Management's Sciclone Pharmaceuticals Inc position peaked at $228K in Q2 2015.
  • 134 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2015.

Based on Highbridge Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.